Iron overload and myelodysplastic syndromes;Surcharge martiale et syndromes myélodysplasiques (SMD)

Transfusion Clinique et Biologique

Volumn 8, Issue 5, 2001, Pages 422-432

  Rose, C ^a   Cambier, N ^a   Mahieu, M ^a   Ernst, O ^b   Fenaux, P ^b  

^a UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Hematochromatosis; Iron overload; Myelodysplastic syndrome; Transfusion

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; ERYTHROPOIETIN; FERRITIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; DYSERYTHROPOIESIS; ERYTHROCYTE TRANSFUSION; HIGH RISK PATIENT; HUMAN; IRON ABSORPTION; IRON OVERLOAD; MACROPHAGE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REFRACTORY ANEMIA; REVIEW; SIDEROBLASTIC ANEMIA;

EID: 17944363261     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(01)00193-8     Document Type: Short Survey

References (93)

1. Myelodysplastic syndromes
2. Red cells II: Acquired anaemias and polycythaemia
3. International scoring system for evaluating prognosis in myelodysplastic syndromes
4. Clinical consequences of acquired transfusional iron overload in adults
5. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations
6. A quantitative evaluation of erythropoiesis in myelodysplastic syndromes using multiparameter flow cytometry
7. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model
8. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
9. Secondary iron overload
10. Clinical manifestations and therapy of transfusional haemosiderosis
11. Iron in the heart. Etiology and clinical significance
12. Natural history of idiopathic refractory sideroblastic anemia
13. The 5q- syndrome: A single-institution study of 43 consecutive patients
14. The 5q- syndrome
15. Proposals for the classification of the myelodysplastic syndromes
16. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
17. A case of hemosiderosis of the liver in myelodysplastic syndrome
18. Radioisotope assessment of heart damage in hypertransfused thalassaemic patients
19. Marked hemosiderosis in myelodysplastic syndrome
20. Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases
21. Hemochromatotic cirrhosis complicating pyridoxine-sensitive hereditary sideroblastic anemia. Case report
22. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes
23. Quantitative measurement of liver iron by needle biopsy
24. Measurement of liver-iron concentration in needle-biopsy specimens
25. Liver injury due to iron overload in thalassemia: Histopathologic and ultrastructural studies
26. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies
27. A 21-year experience with major hemorrhage after percutaneous liver biopsy
28. Platelet function in the myelodysplastic syndromes
29. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: A report on 20 cases
30. Iron overload in patients on hemodialysis is directly related to the number of transfusions
31. Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia
32. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major
33. The non-immune inflammatory response: Serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein
34. Deferoxamine-induced growth retardation in patients with thalassemia major
35. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload
36. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis
37. Results of long-term iron-chelating therapy
38. Magnetic resonance imaging and spectroscopy of hepatic iron overload
39. Hepatic iron overload: Diagnosis and quantification with MR imaging
40. Hepatic iron overload: Quantification with MR imaging at 1.5 T
41. T2 relaxation time study of iron overload in b-thalassemia
42. Quantification of iron level in the liver by MR imaging in patients treated for transfusion siderosis
43. Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver
44. Liver iron overload and liver fibrosis in thalassemia
45. Magnetic resonance imaging of transfusional hepatic iron overload
46. Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: Correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis
47. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients
48. Magnetic resonance imaging of the pituitary gland in patients with secondary hypogonadism due to transfusional hemochromatosis
49. Assessment of tissue iron overload by nuclear magnetic resonance imaging
50. MR findings of secondary hemochromatosis: Transfusional vs erythropoietic
51. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload
52. Magnetic-susceptibility measurement of human iron stores
53. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone
54. Treatment of iron overload in adults with continuous parenteral desferrioxamine
55. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine
56. Iron-chelating therapy and the treatment of thalassemia
57. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
58. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients
59. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
60. Modalities and effectiveness of iron chelation by deferoxamine (DFO) in multitransfused patients with low risk myelodysplastic syndrome (MDS)
61. Chélation du fer et syndromes myélodysplasiques
62. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy
63. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
64. Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)
65. Deferoxamine stability in intravenous solution
66. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload
67. Survival in medically treated patients with homozygous beta-thalassemia
68. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
69. Post-transfusion hemochromatosis Results of a study carried out in Blood Transfusion Centers. Analysis of 15 cases treated with subcutaneous perfusion of Desferal
70. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload
71. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome
72. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
73. Tolerance to deferiprone (L1) in multitransfused patients with myelodysplastic syndrome (MDS). Preliminary results in 9 patients
74. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
75. Physiopathologie et prise en charge de la surcharge en fer transfusionnelle: État actuel de la thérapeutique chélatrice du fer
76. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3- hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site
77. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
78. Safety profile of the oral iron chelator deferiprone: A multicentre study
79. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases
80. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
81. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
82. Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
83. Deferiprone-associated myelotoxicity
84. Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one
85. The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system
86. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: Evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture
87. Results from a phase I clinical trial of HBED
88. HBED: A potential alternative to deferoxamine for iron-chelating therapy
89. HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy
90. A novel oral iron chelator (ICL670A): Results of a phase I single dose safety study
91. Optimizing chelation therapy: Combining deferiprone and desferrioxamine
92. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radio iron probes of hepatocellular and reticulo endothelial iron stores and in iron-loaded rat heart cells in culture